Real-World Data Boost Santhera's Latest DMD Filing, And The Markets Agree

Despite being knocked back twice, Santhera CEO Thomas Meier is still confident Raxone has a place as a Duchenne muscular dystrophy therapy, and believes new long-term data will strengthen its third application to the EU in the coming months.

Dart
Could new data hit the bullseye? • Source: Shutterstock

Having been turned back twice by the European regulators in its pursuit of a Duchenne muscular dystrophy (DMD) indication for Raxone (idebenone), Santhera Pharmaceuticals AG has published the real-world data it believes will prove the doubters wrong.

Latest results from the SYROS study have shown that long-term treatment with idebenone, marketed for Leber’s hereditary optic neuropathy (LHON)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip